# Allogene Wants to Democratize CAR-T. Bispecific Antibodies Already Did. - Date: 2026-04-16 - Category: Biotech & Life Sciences Two approved bispecifics are already delivering what Allogene’s experimental CAR-T hopes to do — without weeks of manufacturing wait. The 2027 readout will determine who wins the lymphoma treatment race. ---